Azetukalner (XEN1101)

No price has been announced for azetukalner, and no budget impact model, cost-effectiveness analysis, or health technology assessment of the product has been published. Xenon Pharmaceuticals reports no products approved for sale and no revenue from product sales. One published forecast, produced by GlobalData and reported by Pharmaceutical Technology in 2024, projects US revenue of $651 million a year by 2035; that forecast predates the Phase 3 X-TOLE2 readout.

Cost benchmarks therefore come from recently launched branded adjunctive antiseizure medications for focal epilepsy. In the US National Average Drug Acquisition Cost file for the week of 16 September 2026, the acquisition cost per tablet was $39.86819 for cenobamate 200 mg, $24.07624 for brivaracetam 100 mg, and $39.07764 for perampanel 12 mg. Across the 2013 to 2023 National Average Drug Acquisition Cost series, the average price of brand-name antiseizure medications rose from $8.71 to $15.43 per unit while generic prices fell from $1.39 to $1.26, widening the brand-to-generic price gap from 1452.39% to 3399.26%. National Average Drug Acquisition Cost is a pharmacy acquisition benchmark, not a wholesale acquisition cost.

Where adjunctive antiseizure medications have been modeled, the modeled budget effect has been favorable, although all such models are non-US. A Belgian budget impact model estimated that introducing cenobamate would reduce the national payer budget by 8,105,616 euros over three years, because reduced seizure-related medical costs offset the drug cost. A budget impact analysis submitted to the Canadian reimbursement review estimated a three-year budget impact of 1,773,123 Canadian dollars in savings. Cost-effectiveness analyses in the United Kingdom, the Netherlands, and Italy each found cenobamate to yield more quality-adjusted life years at lower total cost than brivaracetam, eslicarbazepine acetate, lacosamide, and perampanel.